The global intranasal drug and vaccine delivery market is expected to increase by USD 30.9 billion, at a compound annual growth rate (CAGR) of 6.7% from 2022 to 2028, according to the latest edition of the Global Intranasal Drug and Vaccine Delivery Market Report.

The report covers market size and growth, segmentation, regional breakdowns, competitive landscape, trends and strategies for global intranasal drug and vaccine delivery market. It traces the market’s historic and forecast market growth. The report identifies top segments for opportunities and strategies based on market trends and leading competitors’ approaches. This study also provides an analysis of the impact of the COVID-19 crisis on the intranasal drug and vaccine delivery industry.

This industry report offers market estimates and forecasts of the global market, followed by a detailed analysis of the product, dosage, application, distribution channel, and region. The global market for intranasal drug and vaccine delivery can be segmented by product: powder delivery device, liquid delivery device, pressurized metered dose inhalers, others. According to the research, the liquid delivery device segment had the largest share in the global intranasal drug and vaccine delivery market. Intranasal drug and vaccine delivery market is further segmented by dosage: unit-dose, multi-dose. In 2021, the multi-dose segment made up the largest share of revenue generated by the intranasal drug and vaccine delivery market. Based on application, the intranasal drug and vaccine delivery market is segmented into: respiratory disorders, neurological disorders, vaccination, pain management, others. Among these, the respiratory disorders segment was accounted for the highest revenue generator in 2021. On the basis of distribution channel, the intranasal drug and vaccine delivery market also can be divided into: hospital, retail, online, others. The retail segment captured the largest share of the market in 2021. Intranasal drug and vaccine delivery market by region is categorized into: North America, Europe, Asia-Pacific, MEA (Middle East and Africa), Latin America.

Market Segmentation
By product: powder delivery device, liquid delivery device, pressurized metered dose inhalers, others
By dosage: unit-dose, multi-dose
By application: respiratory disorders, neurological disorders, vaccination, pain management, others
By distribution channel: hospital, retail, online, others
By region: North America, Europe, Asia-Pacific, MEA (Middle East and Africa), Latin America

The report also provides analysis of the key companies of the industry and their detailed company profiles including Aptar Group, Inc., Bespak Europe Ltd., GlaxoSmithKline plc, Glenmark Pharmaceuticals Ltd., Teva Pharmaceutical Industries Ltd., UCB, Inc., among others.
*REQUEST FREE SAMPLE TO GET A COMPLETE LIST OF COMPANIES

Historical & Forecast Period
This research report provides analysis for each segment from 2018 to 2028 considering 2021 to be the base year.

Scope of the Report
– To analyze and forecast the market size of the global intranasal drug and vaccine delivery market.
– To classify and forecast the global intranasal drug and vaccine delivery market based on product, dosage, application, distribution channel, region.
– To identify drivers and challenges for the global intranasal drug and vaccine delivery market.
– To examine competitive developments such as mergers & acquisitions, agreements, collaborations and partnerships, etc., in the global intranasal drug and vaccine delivery market.
– To identify and analyze the profile of leading players operating in the global intranasal drug and vaccine delivery market.

Why Choose This Report
– Gain a reliable outlook of the global intranasal drug and vaccine delivery market forecasts from 2022 to 2028 across scenarios.
– Identify growth segments for investment.
– Stay ahead of competitors through company profiles and market data.
– The market estimate for ease of analysis across scenarios in Excel format.
– Strategy consulting and research support for three months.
– Print authentication provided for the single-user license.